Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for BioRestorative Therapies (BRTX) over the last 12 years, with Q2 2025 value amounting to $2.6 million.

  • BioRestorative Therapies' Other Non-Current Liabilities fell 4255.57% to $2.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.6 million, marking a year-over-year decrease of 4255.57%. This contributed to the annual value of $2.5 million for FY2024, which is 6327.25% up from last year.
  • According to the latest figures from Q2 2025, BioRestorative Therapies' Other Non-Current Liabilities is $2.6 million, which was down 4255.57% from $3.2 million recorded in Q1 2025.
  • BioRestorative Therapies' 5-year Other Non-Current Liabilities high stood at $5.5 million for Q4 2022, and its period low was $1.5 million during Q4 2023.
  • Over the past 4 years, BioRestorative Therapies' median Other Non-Current Liabilities value was $2.9 million (recorded in 2025), while the average stood at $3.2 million.
  • Per our database at Business Quant, BioRestorative Therapies' Other Non-Current Liabilities plummeted by 7213.95% in 2023 and then surged by 6327.25% in 2024.
  • Over the past 4 years, BioRestorative Therapies' Other Non-Current Liabilities (Quarter) stood at $5.5 million in 2022, then crashed by 72.14% to $1.5 million in 2023, then surged by 63.27% to $2.5 million in 2024, then increased by 2.36% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q2 2025, $3.2 million for Q1 2025, and $2.5 million during Q4 2024.